DBV (DBVT) Revenue & Revenue Breakdown
DBV Revenue Highlights
DBV Revenue by Period
DBV Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | - | -100.00% |
| 2022-12-31 | $4.80M | -15.91% |
| 2021-12-31 | $5.71M | -49.38% |
| 2020-12-31 | $11.28M | -23.33% |
| 2019-12-31 | $14.71M | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2017-12-31 | - | -100.00% |
| 2016-12-31 | $202.00K | -8.53% |
| 2015-12-31 | $220.85K | -13.83% |
| 2014-12-31 | $256.29K | 2.09% |
| 2013-12-31 | $251.04K | 8.87% |
| 2012-12-31 | $230.59K | 41.14% |
| 2011-12-31 | $163.37K | - |
DBV generated - in revenue during NA 2023, up -100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
DBV Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | - | -100.00% |
| 2024-03-31 | $1.41M | -84.15% |
| 2023-12-31 | $8.88M | 269.79% |
| 2023-09-30 | $2.40M | 4.90% |
| 2023-06-30 | $2.29M | 4.28% |
| 2023-03-31 | $2.19M | -268.25% |
| 2022-12-31 | $-1.30M | -162.87% |
| 2022-09-30 | $2.07M | 35.64% |
| 2022-06-30 | $1.53M | 100.00% |
| 2022-03-31 | - | -100.00% |
| 2021-12-31 | $5.71M | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | -100.00% |
| 2020-12-31 | $11.28M | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | - |
DBV generated - in revenue during Q2 2024, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
DBV Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| IPHA | Innate Pharma | $51.90M | $16.56M |
| GNFT | Genfit | $28.57M | $17.08M |
| TARS | Tarsus Pharmaceuticals | $17.45M | $40.81M |
| ITOS | iTeos Therapeutics | $12.60M | - |
| IKNA | Ikena Oncology | $9.16M | - |
| MOLN | Molecular Partners | $7.04M | $2.74M |
| CNTA | Centessa Pharmaceuticals | $6.88M | - |
| HCWB | HCW Biologics | $2.84M | $618.85K |
| INBX | Inhibrx | $1.80M | - |
| LYRA | Lyra Therapeutics | $1.56M | $598.00K |
| MNOV | MediciNova | $1.00M | - |
| OPT | Opthea | $108.41K | $61.27K |
| ANEB | Anebulo Pharmaceuticals | - | - |
| RZLT | Rezolute | - | - |
| NUVL | Nuvalent | - | - |
| ELYM | Eliem Therapeutics | - | - |
| EPIX | ESSA Pharma | - | - |
| CELC | Celcuity | - | - |
| ORIC | ORIC Pharmaceuticals | - | - |
| EWTX | Edgewise Therapeutics | - | - |
| DBVT | DBV | - | - |
DBVT Revenue FAQ
What is DBV’s yearly revenue?
DBV's yearly revenue for 2023 was $0, representing a decrease of -100.00% compared to 2022. The company's yearly revenue for 2022 was $4.8M, representing a decrease of -15.91% compared to 2021. DBVT's yearly revenue for 2021 was $5.71M, representing a decrease of -49.38% compared to 2020.
What is DBV’s quarterly revenue?
DBV's quarterly revenue for Q2 2024 was $0, a -100.00% decrease from the previous quarter (Q1 2024), and a -100.00% decrease year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $1.41M, a -84.15% decrease from the previous quarter (Q4 2023), and a -35.87% decrease year-over-year (Q1 2023). DBVT's quarterly revenue for Q4 2023 was $8.88M, a 269.79% increase from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022).
What is DBV’s revenue growth rate?
DBV's revenue growth rate for the last 3 years (2021-2023) was -100.00%, and for the last 5 years (2019-2023) was -100.00%.